Moffitt at ASH
The 63rd installment of the American Society of Hematology (ASH) Annual Meeting was held at the Georgia World Congress Center in Atlanta, Georgia – and virtually – from December 11-14, 2021.
This year, Moffitt authors were listed on 143 abstracts that showcased the latest advances in hematology. In total, there were 52 oral and poster presentations presented by Moffitt authors, three scientific symposia featuring Moffitt speakers; and one education session with a Moffitt speaker.
Moffitt Study Shows Benefit to Giving CAR T-cell Therapy to Patients Sooner
Using cell therapy as a second-line treatment provided better outcomes for lymphoma patients compared to standard of care.
Does Intensifying Lymphodepletion Impact CAR T-Cell Therapy?
Study investigates increasing duration and dosage of chemotherapy in patients with B-cell malignancies.
Do Racial and Ethnic Differences Impact Outcomes in Multiple Myeloma?
“A lot of the genetic and molecular differences we found have direct therapeutic implications,” Moffitt study shows.
UltraCAR-T™ Shows Promise for Treating Myeloid Malignancies
Fast-acting treatment aims to extend lives when minutes matter.
For additional information on Moffitt’s research presented at ASH please reach out to:
Kim Polacek, APR, CPRC
Senior PR Account Coordinator